Breaking News Instant updates and real-time market news.

AMPH

Amphastar

$18.19

0.16 (0.89%)

, PFE

Pfizer

$36.25

0.395 (1.10%)

14:51
11/29/17
11/29
14:51
11/29/17
14:51

Amphastar: FDA approves Medroxyprogesterone Acetate Injectable Suspension

Amphastar Pharmaceuticals (AMPH) announced that the U.S. Food and Drug Administration granted approval of two abbreviated new drug applications for Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL, 1mL vial, and 1mL prefilled syringe, respectively, indicated for the prevention of pregnancy. Amphastar's newly approved products were determined by the FDA to be therapeutically equivalent to Depo-Provera Contraceptive Injection sold in the United States by Pfizer (PFE). Amphastar's CEO, Dr. Jack Zhang, stated: "We are excited about the approval of Medroxyprogesterone Acetate, which further expands the product offerings in our generic injectable portfolio and highlights our commitment and capability of bringing complex generic drugs to the market." Amphastar anticipates launching its product in the first quarter of 2018.

AMPH

Amphastar

$18.19

0.16 (0.89%)

PFE

Pfizer

$36.25

0.395 (1.10%)

  • 29

    Nov

  • 07

    Dec

  • 14

    Dec

AMPH Amphastar
$18.19

0.16 (0.89%)

03/14/17
RAJA
03/14/17
DOWNGRADE
Target $18
RAJA
Outperform
Amphastar downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur downgraded Amphastar Pharmaceuticals to Outperform and lowered his price target for the shares to $18 from $21. The analyst sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product.
03/14/17
03/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Goldman with analyst Doug Clark citing valuation with the stock up 33% since his upgrade back in April of 2016. The analyst keeps a $29 price target for the shares. 2. Amphastar (AMPH) downgraded to Outperform from Strong Buy at Raymond James with analyst Elliot Wilbur saying he sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product. 3. Abbott (ABT) downgraded to Market Perform from Outperform at BMO Capital. 4. GGP (GGP) downgraded to Neutral from Buy at UBS with analyst Jeremy Metz saying he does not see headwinds in the sector easing in the short term and cut his price target for GGP shares to $25 from $28. 5. Harmonic (HLIT) downgraded to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/21/17
WELS
07/21/17
NO CHANGE
WELS
Outperform
Amphastar 'David-vs-Goliath' win over Momenta a major victory, says Wells Fargo
Wells Fargo analyst David Maris said a jury's ruling that a Momenta (MNTA) patent was invalid and unenforceable is a very positive outcome for Amphastar (AMPH) in its "David-vs-Goliath-type" case. While he expects Momenta and partner Novartis' (NVS) Sandoz to appeal, Maris thinks this ruling puts Amphastar in a good position for any future potential settlement talks. Maris does not think investors should "count on any windfall" for Amphastar, but he does think, if approved, this could be an over $50M opportunity and keeps an Outperform rating on the stock, which is up 2% to $18.32 in afternoon trading.
11/09/17
RAJA
11/09/17
DOWNGRADE
RAJA
Market Perform
Amphastar downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Elliot WIlbur downgraded Amphastar to Market Perform after shares have hit his price target and said he sees few catalysts ahead to drive estimates upward.
PFE Pfizer
$36.25

0.395 (1.10%)

11/01/17
UBSW
11/01/17
NO CHANGE
Target $38
UBSW
Buy
Pfizer risk/reward remains favorable, says UBS
UBS analyst Marc Goodman said he continues to like Pfizer's risk/reward following its Q3 results. The analyst believes the company could unlock some value with potential strategic action on its consumer business and also thinks its pipeline gets minimal credit. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.
11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.

TODAY'S FREE FLY STORIES

KURA

Kura Oncology

$14.90

0.75 (5.30%)

10:07
12/11/17
12/11
10:07
12/11/17
10:07
Hot Stocks
Kura Oncology findings supoort tipifarnib development in bone marrow cancers »

Kura Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Hot Stocks
Bioverativ data shows extended dosing with Alprolix provides HepB protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENT

Intersect ENT

$28.60

-1.325 (-4.43%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Recommendations
Intersect ENT analyst commentary  »

Intersect ENT approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CTL

CenturyLink

$15.62

0.9451 (6.44%)

10:04
12/11/17
12/11
10:04
12/11/17
10:04
Technical Analysis
Technical View: CenturyLink higher on Commonwealth of Pennsylvania contract »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$81.99

1.09 (1.35%)

10:03
12/11/17
12/11
10:03
12/11/17
10:03
Hot Stocks
BioMarin highlights new results for valoctocogene roxaparvovec at ASH »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 28

    Feb

ABBV

AbbVie

$96.13

0.18 (0.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$114.46

7.68 (7.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
Alexion reports results from Phase 1b/2 studies of ALXN1210 »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

10:01
12/11/17
12/11
10:01
12/11/17
10:01
General news
JOLTS Job Openings data reported »

October JOLTS Job…

CELG

Celgene

$106.09

3.36 (3.27%)

10:00
12/11/17
12/11
10:00
12/11/17
10:00
Options
Sizable put spread in Celgene as shares see strength »

Sizable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

MARK

Remark Holdings

$8.84

1.43 (19.30%)

09:59
12/11/17
12/11
09:59
12/11/17
09:59
Conference/Events
Remark Holdings management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CTL

CenturyLink

$15.47

0.795 (5.42%)

, FTR

Frontier Communications

$9.75

0.6 (6.56%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Options
Early notable gainers among liquid option names on December 11th »

Notable gainers among…

CTL

CenturyLink

$15.47

0.795 (5.42%)

FTR

Frontier Communications

$9.75

0.6 (6.56%)

SWN

Southwestern Energy

$5.72

0.225 (4.10%)

MNK

Mallinckrodt

$22.64

0.34 (1.52%)

WYNN

Wynn Resorts

$159.54

0.62 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 14

    Dec

ECR

Eclipse Resources

$2.36

0.21 (9.77%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLE

Energy Select Sector SPDR

$69.57

0.29 (0.42%)

09:54
12/11/17
12/11
09:54
12/11/17
09:54
Technical Analysis
Technical View: Energy Select Sector SPDR leads on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$61.50

0.195 (0.32%)

09:51
12/11/17
12/11
09:51
12/11/17
09:51
Upgrade
Nike rating change  »

Follow-up: Nike upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

ECR

Eclipse Resources

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.